0001642380-26-000008
SEC filingStrategic pivot from lab services to transplant kitted tests crushed Q1 revenue 98.5% to $32K, but non-cash contingent consideration gain narrowed net loss 35.7% to $4.3M amid ongoing R&D for commercialization.
Laboratory Services revenue declined 98.5% to $32K from $2.1M in Q1 FY2025, reflecting management's deliberate shift in focus toward commercializing transplant kitted tests and deploying sales personnel to sign new laboratory customers for these products, as noted in MD&A. This pivot from traditional services to a higher-margin, decentralized testing model preserved gross margin at 46.9% despite minimal volume, with gross profit at $15K versus $1.3M YoY. The change aligns costs to the strategic reprioritization but exposes topline vulnerability until kitted test adoption ramps, amid Bio-Rad dependency for ongoing operations and performance targets.
Net cash used in operating activities was $7.6M, with free cash flow at -$8.3M after $613K in capital expenditures (up from $307K YoY), funding working capital, human capital, equipment, leases, business development, IP investments, and clinical trials as described in MD&A. Cash requirements stem from these investing and operating activities essential to transplant diagnostics push. Commercialization expenses will depend on capital access, with MD&A noting risks from inflation eroding purchasing power and inability to pass cost increases in competitive healthcare amid payor pressures.
Management anticipates ongoing operating losses and negative cash flows near-term due to the transplant commercialization shift impacting lab revenue. Heavy reliance on Bio-Rad concentrates business volume and ties performance to the partnership. Inflation persistence could accelerate expense growth beyond expectations, hastening capital utilization in this capital-intensive diagnostics transition.